Research
Hormonal
Continuous Glucose Monitoring (CGM) and closed-loop 'artificial pancreas' systems significantly enhance glycemic control and reduce hypoglycemia risk by providing real-time data and automated insulin delivery.
If you use insulin, ask your doctor about Continuous Glucose Monitoring (CGM). These devices track your blood sugar 24/7 and can even automatically adjust insulin delivery (artificial pancreas). This reduces the risk of dangerous low blood sugar and helps you maintain better control without constant finger pricks.
ModerateSupportsMEDIUM confidence
CGM devices, in contrast, provide a continuous flow of glucose data, enabling a more comprehensive assessment of an individual’s glycemic profile. ... Certain CGM systems have the capability to seamlessly integrate with insulin pumps, facilitating the process of automated insulin delivery. This advanced functionality is commonly referred to as an artificial pancreas or closed-loop system. ... These closed-loop systems employ predictive algorithms to enhance glycemic control, thereby alleviating the burden of diabetes management for patients.
Why this rating
Review article summarizing technological advancements and their benefits.
Source
Advances in the Management of Diabetes Mellitus: A Focus on Personalized Medicine
Fnu Sugandh et al. · Cureus · 2023
DOI 10.7759/cureus.43697
narrative_reviewCited 258×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Personalized medicine, utilizing genetic screening and pharmacogenomics, improves diabetes management outcomes by tailoring treatment plans to individual genetic makeup, lifestyle, and health characteristics, thereby optimizing medication choices and reducing adverse reactions.Moderate
- Personalized glycemic targets, adjusted for age, comorbidities, and hypoglycemia risk, improve patient outcomes by minimizing severe hypoglycemic events and enhancing quality of life, compared to rigid standard targets.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →